Brief: Harpoon Therapeutics Announces Updated Interim Tolerability And Response Data From Phase 1/2 Clinical Trial Of T Cell Engager Hpn328
21/10/2023 17:30
Oct 21 (Reuters) - Harpoon Therapeutics Inc HARP.O :
* HARPOON THERAPEUTICS ANNOUNCES UPDATED INTERIM
TOLERABILITY AND
RESPONSE DATA FROM PHASE 1/2 CLINICAL TRIAL OF T CELL ENGAGER
HPN328 AT ESMO CONGRESS 2023
* HARPOON-CONFIRMED RESPONSE RATE 35% ACROSS ALL TUMOR
TYPES,PATIENT COHORTS TREATED WITH 1 MG PRIMING DOSE, INCLUDING
3 CONFIRMED,COMPLETE RESPONSES
* HPN328 WAS GENERALLY WELL TOLERATED ACROSS ALL DOSE
COHORTS
(N=71)
Source text for Eikon: ID:nGNX6y5cFZ
Further company coverage: HARP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Harpoon Therapeutics
See all newsBrief: Harpoon Therapeutics Receives 17 Additional Demands Seeking Disclosures in Proxy Statement
U.S. RESEARCH ROUNDUP-Axonics, BlackRock, Credit Acceptance
U.S. STOCKS ON THE MOVE-Core & Main, Commercial Metals, Equifax
U.S. STOCKS ON THE MOVE-Toll Brothers, American Eagle Outfitters, Twilio
Wrapup 1: Drugmakers kick off industry conference with two cancer deals